Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.38 USD | -1.83% | -.--% | +74.10% |
Sales 2024 * | 12Cr 13Cr 1.11TCr | Sales 2025 * | 33Cr 35Cr 2.94TCr | Capitalization | 258.19Cr 280Cr 23TCr |
---|---|---|---|---|---|
Net income 2024 * | -43Cr -47Cr -3.89TCr | Net income 2025 * | -12Cr -13Cr -1.05TCr | EV / Sales 2024 * | 21.8 x |
Net Debt 2024 * | 8.93Cr 9.68Cr 808.06Cr | Net cash position 2025 * | 9.47Cr 10Cr 857.07Cr | EV / Sales 2025 * | 7.65 x |
P/E ratio 2024 * |
-6.08
x | P/E ratio 2025 * |
-33
x | Employees | 464 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 17.23% |
Latest transcript on MorphoSys AG
1 day | -1.83% | ||
3 months | +1.57% | ||
6 months | +179.26% | ||
Current year | +74.10% |
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 01/19/01 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 07/23/07 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 17/18/17 |
Director/Board Member | 67 | 17/18/17 | |
Marc Cluzel
CHM | Chairman | 69 | 31/12/31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.36% | 5.46TCr | |
-5.31% | 3.99TCr | |
+37.52% | 3.88TCr | |
+14.75% | 2.69TCr | |
-12.56% | 2.62TCr | |
-22.45% | 1.88TCr | |
+25.12% | 1.22TCr | |
+0.04% | 1.22TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- MOR Stock
- MPSYF Stock